News & Updates

In the treatment of adults with hospital-associated (HABP) or ventilator-associated bacterial pneumonia (VABP), the β-lactam/β-lactamase inhibitor combination imipenem/cilastatin/relebactam appears to be as good as piperacillin/tazobactam, with similar safety profiles, according to a phase III trial.

Use of topical testosterone therapy in addition to supervised exercise training does little to improve long-distance walking ability for older women recovering from a hip fracture, according to the phase III STEP-HI randomized clinical trial.

Treatment with seladelpar led to improvements in markers of cholestasis and liver injury in patients with primary biliary cholangitis (PBC) and compensated cirrhosis, according to an additional analysis of the RESPONSE trial presented at DDW 2025.

In the treatment of eosinophilic oesophagitis, the use of etrasimod is well tolerated and results in sustained histological and endoscopic improvements and symptom reduction, according to the results of a phase II study.

The galectin-3 (Gal3) inhibitor belapectin, given at the established 2-mg dose, demonstrates its treatment potential for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension (PH) in the phase IIb/III NAVIGATE trial.

This article will summarize the latest developments in the first-line management of advanced EGFRm NSCLC and highlight key consideration factors.

The glucagon-like peptide-1 (GLP-1) and fibroblast growth factor 21 (FGF21) dual agonist HEC88473 demonstrates an acceptable safety profile and potential efficacy in the management of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM).